JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $71 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler reiterated a Market Outperform rating on Cytokinetics (NASDAQ:CYTK) and maintained a $71 price target.
May 22, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jason Butler reiterated a Market Outperform rating on Cytokinetics and maintained a $71 price target.
The reiteration of a Market Outperform rating and maintenance of a $71 price target by JMP Securities analyst Jason Butler indicates a positive outlook for Cytokinetics' stock in the short term. This news is highly relevant and important for investors, as it suggests potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100